Pharmacokinetic interactions between HIV antiretroviral therapy and drugs used to treat opioid dependence

Expert Opinion on Drug Metabolism and Toxicology

Volumn 2, Issue 4, 2006, Pages 533-543

  Maas, Benjamin ^a   Kerr, Thomas ^a,b   Fairbairn, Nadia ^a   Montaner, Julio ^a,b   Wood, Evan ^a,b  

^a ST PAUL S HOSPITAL   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Antiretrovirals; HAART; Methadone; Opioids

Indexed keywords

ANTIRETROVIRUS AGENT; DIAMORPHINE; ILLICIT DRUG; OPIATE; ACETYLMETHADOL; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BUPRENORPHINE; METHADONE; NARCOTIC AGENT; NARCOTIC ANTAGONIST;

DRUG ABUSE; DRUG DEPENDENCE; DRUG METABOLISM; DRUG USE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; PREVALENCE; REVIEW; RISK FACTOR; SEROCONVERSION; SUBSTITUTION THERAPY; ANIMAL; DRUG INTERACTION; OPIATE ADDICTION;

ANIMALS; ANTI-HIV AGENTS; BUPRENORPHINE; DRUG INTERACTIONS; HUMANS; METHADONE; METHADYL ACETATE; NARCOTIC ANTAGONISTS; NARCOTICS; OPIOID-RELATED DISORDERS;

EID: 33747845304     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425255.2.4.533     Document Type: Review

References (80)

1. GOUREVITCH MN, FRIEDLAND GH: Interactions between methadone and medications used to treat HIV infection: a review. Mt. Sinai J. Med. (2000) 67(5-6):429-436. A very thorough review article of interactions between methadone and antiretrovirals covering studies up to 2000. Includes charts summarising interactions for clinical reference.
2. FARAGON JJ, PILIERO PJ: Drug interactions associated with HAART: focus on treatments for addiction and recreational drugs. AIDS Read. (2003) 13(9):433-434, 437-441, 446-450. Includes an extensive section on interactions with methadone as well as other nonopioid recreational drugs. Useful table summarising studies and unknown areas as of 2003.
3. UNAIDS: 2004 Report on the global AIDS epidemic. UNAIDS (2004).
4. KERR T, WODAK A, ELLIOTT R, MONTANER JS, WOOD E: Opioid substitution and HIV/AIDS treatment and prevention. Lancet (2004) 364(9449):1918-1919.
5. GIBSON DR, FLYNN NM, PERALES D: Effectiveness of syringe exchange programs in reducing HIV risk behavior and HIV seroconversion among injecting drug users. AIDS (2001) 15(11):1329-1341.
6. STRATHDEE SA, PALEPU A, CORNELISSE PG et al.: Barriers to use of free antiretroviral therapy in injection drug users. JAMA (1998) 280(6):547-549.
7. FARRE M, MAS A, TORRENS M, MORENO V, CAMI J: Retention rate and illicit opioid use during methadone maintenance interventions: a meta-analysis. Drug Alcohol Depend. (2002) 65(3):283-290.
8. WORLD HEALTH ORGANIZATION UNOODAC, UNAIDS: Substitution maintenance therapy in the management of opioid dependence and HIV/AIDS prevention: position paper (2004).
9. WOOD E, MONTANER JS, BANGSBERG DR et al.: Expanding access to HIV antiretroviral therapy among marginalized populations in the developed world. AIDS (2003) 17(17):2419-2427.
10. ANTELA A, CASADO JL, GONZALEZ MJ et al.: Influence of a methadone maintenance programme on the improved outcome of a cohort on injecting drug users with advanced HIV disease. AIDS (1997) 11(11):1405-1406.
11. CAPLEHORN JR, ROSS MW: Methadone maintenance and the likelihood of risky needle-sharing. Int. J. Addict. (1995) 30(6):685-698.
12. CAPLEHORN JR, DALTON MS, HALDAR F, PETRENAS AM, NISBET JG: Methadone maintenance and addicts' risk of fatal heroin overdose. Subst. Use Misuse (1996) 31(2):177-196.
13. MOATTI JP, CARRIERI MP, SPIRE B et al.: Adherence to HAART in French HIV-infected injecting drug users: the contribution of buprenorphine drug maintenance treatment. The Manif 2000 study group. AIDS (2000) 14(2):151-155.
14. ADDICTION NCDPOEMTOO: Effective medical treatment of opiate addiction. National Consensus Development Panel on Effective Medical Treatment of Opiate Addiction. JAMA (1998) 280(22):1936-1943.
15. HOGG RS, YIP B, KULLY C et al.: Improved survival among HIV-infected patients after initiation of triple-drug antiretroviral regimens. CMAJ (1999) 160(5):659-665.
16. HAMMER SM, SQUIRES KE, HUGHES MD et al.: A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N. Engl J. Med. (1997) 337(11):725-733.
17. CARPENTER CC, COOPER DA, FISCHL MA et al.: Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel. JAMA (2000) 283(3):381-390.
18. WOOD E, MONTANER JS, YIP B et al.: Adherence and plasma HIV RNA responses to highly active antiretroviral therapy among HIV-1 infected injection drug users. CMAJ (2003) 169(7):656-661.
19. BANGSBERG DR, HECHT FM, CHARLEBOIS ED et al.: Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS (2000) 14(4):357-366.
20. KERR T, PALEPU A, BARNESS G et al.: Psychosocial determinants of adherence to highly active antiretroviral therapy among injection drug users in Vancouver. Antivir. Ther. (2004) 9(3):407-414.
21. PALEPU A, HORTON NJ, TIBBETTS N, MELI S, SAMET JH: Uptake and adherence to highly active antiretroviral therapy among HIV-infected people with alcohol and other substance use problems: the impact of substance abuse treatment. Addiction (2004) 99(3):361-368.
22. RAINEY P: HIV drug interactions: the good, the bad, and the other. Ther. Drug Monit. (2002) 24(1):26-31.
23. HANSTEN PD: Drug Interactions. In: Applied Therapeutics: Clinical Use of Drugs (6th edn). MA Koda-Kimble, LY Young (Eds), Applied Therapeutics, Inc., Vancouver, WA, USA (1995).
24. FERRARI A CC, BERTOLINI A, STERNIERI E: Methadone - metabolism, pharmacokinetics and interactions. Pharmacol. Res. (2004) 50(6):551-559.
25. HARDMAN JG LL, GILMAN AG: Goodman & Gilmans's The Pharmacological Basis of Therapeutics. McGraw-Hill Professional, New York, USA (2001).
26. SCHWARTZ EL BA, KAHL P, MILLER MA, SELWYN PA, FRIEDLAND GH: Pharmacokinetic interactions of zidovudine and methadone in intravenous drug-using patients with HIV infection. J. Acquir. Immune Defic. Syndr. (1992) 5(6):619-626.
27. MCCANCE-KATZ EF, RAINEY PM, JATLOW P, FRIEDLAND G: Methadone effects on zidovudine disposition (AIDS Clinical Trials Group 262). J. Acquir. Immune Defic. Syndr. (1998) 18(5):435-443.
28. MCCANCE-KATZ EF, RAINEY PM, FRIEDLAND G, KOSTEN TR, JATLOW P: Effect of opioid dependence pharmacotherapies on zidovudine disposition. Am. J. Addict. (2001) 10(4):296-307.
29. RAINEY PM FG, SNIDOW JW, MCCANCE-KATZ EF et al.: The pharmacokinetics of methadone following co-administration with a lamivudine/zidovudine combination tablet in opiate-dependent subjects. Am. J. Addict. (2002) 11(1):66-74.
30. RAINEY PM, FRIEDLAND G, MCCANCE-KATZ EF et al.: Interaction of methadone with didanosine and stavudine. J. Acquir. Immune Defic. Syndr. (2000) 24(3):241-248.
31. FRIEDLAND G, RAINEY PM, JATLOW P et al.: Pharmacokinetics (pK) of didanosine (ddl) from encapsulated enteric coated bead formulation (EC) versus chewable tablet formulation (EC) in patients (pts) on chronic methadone therapy. In: Program and abstracts of the XIV International AIDS Conference. Barcelona, Spain (2002). Abstract TuPeB4548.
32. SELLERS E, LAM R, MCDOWELL J, AL E: The pharmacokinetics (PK) of abacavir (ABC) and methadone (M) following coadministration: CNAA1012. In: Program and abstracts of the 39th Interscience Cionfer-on Antimicrobial Agents and Chemotherapy. San Francisco, USA (1999). Abstract 663.
33. SMITH P, KEARNEY B, CLOEN D et al.: Tenofovir DF does not affect the pharmacokinetics or pharmacodynamics of methadone. In: Program and abstracts of the 2nd International AIDSSociety Conference on HIV Pathogenesis and Treatment. Paris, France (2003) Abstract 869.
34. CLARKE SM, MULCAHY FM, TJIA J et al.: Pharmacokinetic interactions of nevirapine and methadone and guidelines for use of nevirapine to treat injection drug users. Clin. Infect. Dis. (2001) 33(9):1595-1597.
35. STOCKER H, KRUSE G, KRECKEL P et al.: Nevirapine significantly reduces the levels of racemic methadone and (R)-methadone in human inmmunodeficiency virus-infected patients. Antimicrob. Agents Chemother. (2004) 48:4148-4153.
36. HEELON MW, MEADE LB: Methadone withdrawal when starting an antiretroviral regimen including nevirapine. Pharmacotherapy (1999) 19:471-472.
37. ALTICE FL, FRIEDLAND GH, COONEY EL: Nevirapine induced opiate withdrawal among injection drug users with HIV infection receiving methadone. AIDS (1999) 13(8):957-962.
38. OTERO MJ, FUERTES A, SANCHEZ R, LUNA G: Nevirapine-induced withdrawal symptoms in HIV patients on methadone maintenance programme: an alert [letter]. AIDS (1999) 13 (8):1004-1005.
39. STASZEWSKI S, HARBERL A, GUTE P, NISIUS G, MILER V, CARLEBACH A: Nevirapine/didanosine/lamivudine once daily in HIV-1 infected intravenous drug users. Antivir. Ther. (1998) 3:55-56.
40. CLARKE SM, MULCAHY FM, TJIA J et al.: The pharmacokinetics of methadone in HIV-positive patients receiving the non-nucleoside reverse transcriptase inhibitor efavirenz. Br. J. Clin. Pharmacol. (2001) 51(3):213-217.
41. MARZOLINI C, TROILLET N, TELENTI A et al.: Efavirenz decreases methadone blood concentrations. AIDS (2000) 14:1291-1292.
42. BOFFITO M, ROSSATI A, DAL CONTEI et al.: Opiate withdrawal syndrome in new efavirenz recipients under methadone maintenance regimen. 1st IAS Conference on HIV Pathogenesis and Treatment. Buenos Aires, Brazil (2001).
43. PINZANI V, FAUCHERRE V, PEYRIERE H, BLAYAC JP: Methadone withdrawal symptoms with nevirapine and efavirenz. Ann. Pharmacother. (2000) 34(3):405-407.
44. MCCANCE-KATZ EF, RAINEY P, SMITH P et al.: Drug interactions between opioids and amiretriviral medications: interaction between methadone, LAAM, and delavirdine. Am. J. Addict. (2006) 15(1):23-34.
45. BOOKER B, SMITH P, FORREST A et al.: Lack of effect of methadone (MET) on the pharmacokinetics (PK) of delavirdine (DLV) & N-delavirdine [abstract A 490]. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, USA (2001):14.
46. MOYLE GJ, BACK D: Principles and practice of HIV-protease inhibitor pharmacoenhancement. HIV Med. (2001) 2(2):105-113.
47. IRIBARNE C, BERTHOU F, CARLHANT D et al.: Inhibition of methadone and buprenorphine N-dealkylations by three HIV-1 protease inhibitors. Drug Metab. Dispos. (1998) 26(3):257-260.
48. HSU A, GRANNEMAN GR, CAROTHERS L et al.: Ritonavir does not increase methadone exposure in healthy volunteers. In: Program and abstracts of the 5th Conference on Retroviruses and Opportunistic Infections. Chicago, IL, USA (1998). Abstract 342.
49. GELETKO SM, ERICKSON AD: Decreased methadone effect after ritonavir initiation. Pharmacotherapy (2000) 20(1):93-94.
50. MCCANCE-KATZ EF, RAINEY P, FRIEDLAND G, JATLOW P: The protease inhibitor lopinavir-ritonavir may produce opiate withdrawal in methadone-maintained patients. Clin. Infect. Dis. (2003) 37(4):476-482.
51. GERBER JG, ROSENKRANZ S, SEGAL Y et al.; ACTG 401 STUDY TEAM: Effect of ritonavir/saquinavir on stereoselective phamaco kinetics of methadone: results of AIDS Clinical Trials Group (ACTG) 401. J. Acquir. Immune Defic. Syndr. (2001) 27:153-160.
52. SHELTON MJ, CLOEN D, DIFRANCEXCO R et al.: The effects of once-daily saquinavir/minidose ritonavir on the pharmacokinetics of methadone. J. Clin. Pharmacol. (2004) 44(3):293-304.
53. SHELTON MJ, CLOEN D et al.: Pharmacokinetics (PK) of once daily (QD) saquinavir/ritonavir (SQV/RTV): effects on unbound methadone and alpha1 acid-glycoprotein (AAG). In: Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, USA (2001). Abstract A-492.
54. CANTILENA L, MCCREA J, BLAZES D et al.: Lack of a pharmacokinetic interaction between indinavir and methadone. Clin Pharmacol Ther. (1999) 65(135):Abstract PI-74.
55. MCCANCE-KATZ EF, FARBER S, SELWYN PA, O'CONNOR A: Decrease in methodone levels with nelfinavir mesylate [letter]. Am. J. Pychiat. (2000) 157(3):481.
56. HSYU PH, LILLIBRIDGE JH, MAROLDO L, WEISS WR, KERR BM: Pharmacokinetic (PK) and pharmacodynamic (PD) interactions between nelfinavir and methadone. In: Program and abstracts of the 7th Conference on Retroviruses and Opportunistic Infections. San Francisco, USA (2000). Abstract 87.
57. SMITH PF, BOOKER BM, DIFRANCESCO R et al.: Effect of methadone or LAAM on the pharmacokinetics of nelfinavir and M8. In: Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, USA (2001). Abstract A-491.
58. AGENERASE [package insert]. GlaxoSmithWine, Research Triangle Park, NC, USA (1999).
59. BART PA, RIZZARDI P, GALLANT S et al.: Methadone blood concentrations are decreased by the administration of abacavir plus amprenavir. Ther. Drug Monit. (2001) 23(5):553-555.
60. CLARKE S, MULCAHY F, BERGIN C et al.: Absence of opioid withdrawal symptoms in patients receiving methadone and the protease inhibitor lopinavir/ritonavir. Clin. Infect. Dis. (2002) 34:1143-1145.
61. REYATAZ [package insert]. Bristol-Myers Squibb, Princeton, NJ, USA.
62. PERLOFF ES, DUAN SX, SKOLNIK PR, GREENBLATT DJ, VON MOLTKE LL: Atazanavir: effects on P-glycoprotein transport and CYP3A metabolism in vitro. Drug Metab. Dispos. (2005) 33:764-770.
63. FRIEDLAND G, ANDREWS L, SCHREIBMAN T et al.: Lack of an effect of atazanavir on steady-state pharmacokinetics of methadone in patients chronically treated for opiate addiction. AIDS (2005) 19(15):1635-1641.
64. TIPRANAVIR [package insert]. Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT, USA (2005).
65. JOHNSON RE, JAFFE JH, FUDALA PJ: A controlled trial of buprenorphine treatment for opiate dependence. JAMA (1992) 267:2750-2755.
66. LING W, CHARUVASTRA C, COLLINS JF et al.: Bu prenorphine maintenance treatment of opiate dependence: a multicenter, randomized clinical trial. Addiction (1998) 93:475-486.
67. JOHNSON RE, CHUTUAPE M, STRAIN EC, WALSH SL, STITZER ML, BIGELOW GE: A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. N. Engl. J. Med. (2000) 343:1290-1297.
68. KOBAYASHI K, YAMAMOTO T, CHIBA K et al.: Human buprenorphine N-dealkylation is catalyzed by cytochrome P450 3A4. Drug Metab. Dispos. (1998) 26:818-821.
69. MCCANCE-KATZ EF, PADE P, FRIEDLAND G, MORSE G, MOODY D, RAINEY P: Efavirenz decreases buprenorphine exposure, but is not associated with opiate withdrawal in opioid-dependent individuals. 12th conference on Retroviruses and Opportunistic Infections. Boston, MA, USA (2005). Abstract 653.
70. PADE P, EXHEM-WILLIAMS C, HELLEW L et al.: Buprenorphine does not alter efavirenz pharmacokinetics [abstract 101]. In: Program and abstracts of the 66th Annual Scientific Meeting of the College on Problems of Drug Dependence (San Juan, Puerto Rico). Philadelphia: College on Problems of Drug Dependence (2004):16.
71. MCCANCE-KATZ E: Treatment of opioid dependence and coinfection with HIV and hepatitis C virus in opioid-dependent patients: the importance of drug interactions between opioids and antiretroviral agents. Clin. Infect. Dis. (2005) 41(Suppl. 1):S89-S95.
72. BRUCE RD, ALTICE FL: Three case reports of a clinical pharmacokinetic interaction with buprenorphine and atazanavir plus ritonavir. AIDS (2006) 20(5):783-784.
73. ORLAAM [package insert]. Roxane Pharmaceutical, Columbus, Ohio, USA (2002).
74. MCCANCE-KATZ EF, RAINEY PM, SMITH P et al.: Drug interactions between opioids and antiretroviral medications: interaction between methadone, LAAM, and nelfinavir. Am. J. Addict. (2004) 13(2):163-180.
75. CLARKE SM, MULCAHY F: Antiretroviral therapy for drug users. Int. J. STD AIDS (2000) 11(10):627-631.
76. GROSS R, BILKER WB, FRIEDMAN HM, COYNE JC, STROM BL: Provider inaccuracy in assessing adherence and outcomes with newly initiated antiretroviral therapy. AIDS (2002) 16(13):1835-1837.
77. http://www.atforum.com/SiteRoot/pages/add iction_resources/ Drug_Interactions.pdf LEAVITT S: Methadone-Drug Interactions 3rd Edition. Addiction Treatment Forum (2005).
78. http://www.fuzeon.com/common/fpi.pdf Product information. T-20 (fuzeon). This site provides updated charts summarising studies on the interaction between antiretrovirals and methadone and includes brief clinical recommendations for coadministration.
79. http://www.tthhivclinic.com Antiretroviral-methadone interactions. St. Michael's Hospital & Alice Tseng, PharmD, Toronto General Hospital (2005).
80. http://www.hiv-druginteractions.org Liverpool HIV Pharmacology Group. HIV drug interactions website.